Phospho-BCL2L11 (Ser69) Antibody

What is BCL2L11 (BIM) and its significance in apoptosis?

BCL2L11, commonly known as BIM, is a pro-apoptotic member of the BCL-2 protein family that plays a crucial role in the regulation of programmed cell death. BIM exists in multiple isoforms including BIM EL, BIM L, and BIM S, with the shortest form (BIM S) being the most cytotoxic and generally only transiently expressed during apoptosis. BIM EL and BIM L isoforms can be sequestered to the dynein motor complex through interaction with dynein light chain and are released during apoptotic signaling. This release mechanism represents a key regulatory step in the initiation of apoptosis in response to various cellular stresses and death signals .

How does phosphorylation at Ser69 regulate BIM activity?

Phosphorylation of BIM at Ser69 (Ser65 in mouse and rat) occurs primarily through the Erk1/2-dependent pathway in response to growth factor stimulation. This post-translational modification promotes proteasome-mediated degradation of BIM, particularly the BIM EL isoform, thereby enhancing cell survival. This represents a critical regulatory mechanism whereby growth factors can protect cells from apoptosis by targeting pro-apoptotic BIM for degradation. In contrast, environmental stress can trigger BIM phosphorylation by JNK at different sites, resulting in dissociation from the dynein complex and increased apoptotic activity .

What are the species cross-reactivity patterns for Phospho-BIM (Ser69) antibodies?

Commercially available Phospho-BIM (Ser69) antibodies typically demonstrate reactivity with human and mouse samples. The antibody recognizes endogenous levels of BIM protein only when phosphorylated at Ser69. The antigen sequence used to produce some antibodies shares 100% sequence homology with multiple species, though confirmed reactivity is typically limited to human and mouse samples. Researchers should verify reactivity when working with other species, even those with high sequence homology .

How does BIM phosphorylation relate to the broader BCL-2 family phosphorylation network?

BIM phosphorylation is part of a complex network of post-translational modifications affecting multiple BCL-2 family members. For example, BCL-2 itself is phosphorylated at residues Ser70, Ser87, and Thr69 within its unstructured loop during G2/M phase of the cell cycle and in response to microtubule-damaging agents. This phosphorylation inactivates BCL-2's anti-apoptotic function, making cells more susceptible to death signals during specific phases of the cell cycle. Both BIM and BCL-2 phosphorylation events represent key regulatory mechanisms that reset susceptibility to apoptosis in response to various cellular conditions and signals .

How do different kinase pathways differentially regulate BIM Ser69 phosphorylation versus other phosphorylation sites?

BIM phosphorylation occurs through distinct kinase pathways that can have opposing effects on its pro-apoptotic activity. Erk1/2-dependent phosphorylation at Ser69 promotes degradation and reduces apoptotic activity, whereas JNK-mediated phosphorylation at other sites (not Ser69) typically enhances BIM's pro-apoptotic function by promoting its release from sequestration. This dichotomy highlights the complexity of BIM regulation through phosphorylation. Additionally, studies suggest that the ASK1/JNK1 pathway, which phosphorylates BCL-2 during normal cell cycle progression at G2/M phase, may also influence BIM phosphorylation status indirectly through crosstalk between these pathways. Researchers investigating these pathways should employ specific inhibitors of Erk1/2 (e.g., U0126, PD98059) and JNK (e.g., SP600125) to dissect the relative contributions of these kinases to BIM phosphorylation in their experimental systems .

What is the temporal relationship between BIM phosphorylation at Ser69 and subsequent proteasomal degradation?

Following growth factor stimulation, Erk1/2-dependent phosphorylation of BIM at Ser69 occurs rapidly (typically within 15-30 minutes) and precedes proteasomal degradation, which may take several hours to complete. This temporal separation allows for precise experimental tracking of the phosphorylation-degradation cascade. Researchers can leverage this timeline by designing pulse-chase experiments with protein synthesis inhibitors (cycloheximide) and proteasome inhibitors (MG132, bortezomib) to quantify the half-life of phosphorylated versus non-phosphorylated BIM. The kinetics of this process can vary significantly between cell types and in response to different growth factors, necessitating optimization for each experimental system .

How does cell cycle progression affect BIM phosphorylation compared to other BCL-2 family members?

Similar to BCL-2, which undergoes phosphorylation specifically during G2/M phase, BIM phosphorylation status may also fluctuate throughout the cell cycle. Evidence suggests that stress response kinases activated during mitosis may simultaneously regulate multiple BCL-2 family members to modulate apoptotic sensitivity at specific cell cycle checkpoints. Cell elutriation techniques combined with phospho-specific antibody detection can reveal whether BIM Ser69 phosphorylation follows similar cell cycle-dependent patterns as observed with BCL-2. This is particularly relevant for understanding the differential susceptibility of cancer cells to apoptosis during various phases of the cell cycle and may inform the timing of anti-cancer therapies targeting the BCL-2 family .

How does the three-dimensional structural conformation of BIM change upon Ser69 phosphorylation?

Phosphorylation of BIM at Ser69 likely induces conformational changes that expose recognition motifs for E3 ubiquitin ligases, facilitating its subsequent ubiquitination and proteasomal degradation. While the unstructured loop regions of BCL-2 family proteins are known to be important for post-translational regulation, the precise structural consequences of phosphorylation remain incompletely characterized. Advanced biophysical techniques such as circular dichroism, fluorescence resonance energy transfer (FRET), and nuclear magnetic resonance (NMR) spectroscopy can be employed to elucidate these structural changes. Understanding these conformational alterations may facilitate the design of small molecule inhibitors that specifically target phosphorylated BIM or prevent its phosphorylation-induced degradation .

What are the optimal conditions for detecting Phospho-BIM (Ser69) by Western blotting?

For optimal western blotting detection of Phospho-BIM (Ser69), researchers should adhere to the following protocol:

• Lyse cells in buffer containing phosphatase inhibitors (sodium fluoride, sodium orthovanadate, and phosphatase inhibitor cocktail) to preserve phosphorylation status

• Use fresh lysates whenever possible to minimize dephosphorylation

• Separate proteins on 12-15% SDS-PAGE gels for optimal resolution of BIM isoforms (23-26 kDa)

• Transfer to PVDF membrane (preferred over nitrocellulose for phospho-proteins)

• Block with 5% BSA (not milk, which contains phosphatases) in TBST

• Incubate with Phospho-BIM (Ser69) antibody at 1:1000 dilution overnight at 4°C

• Wash extensively with TBST (at least 3 × 10 minutes)

• Use HRP-conjugated secondary antibodies and enhanced chemiluminescence detection

Control treatments with lambda phosphatase can confirm signal specificity, while parallel blotting with total BIM antibody allows calculation of the phospho-to-total BIM ratio for accurate quantification .

What are the key considerations for immunoprecipitation experiments using Phospho-BIM (Ser69) antibody?

When conducting immunoprecipitation with Phospho-BIM (Ser69) antibody, researchers should:

• Start with at least 500 μg of total protein lysate to ensure sufficient target protein

• Pre-clear lysates with protein A beads for 30 minutes to reduce non-specific binding

• Use the recommended antibody dilution (1:50) and incubate overnight at 4°C

• Capture immune complexes with protein A beads for 1-2 hours

• Perform stringent washes (4-5 times) with RIPA buffer to reduce background

• Elute bound proteins by boiling in SDS sample buffer

• Analyze immunoprecipitates by western blotting with total BIM antibody

This technique is particularly valuable for studying BIM interactions with other proteins following phosphorylation, such as E3 ubiquitin ligases or components of the proteasomal degradation machinery .

How can phosphorylation-deficient BIM mutants be generated and validated for functional studies?

To study the specific role of Ser69 phosphorylation in BIM function, phosphorylation-deficient mutants can be generated using site-directed mutagenesis to replace Ser69 with alanine (S69A), preventing phosphorylation. Conversely, phosphomimetic mutants replacing Ser69 with aspartic or glutamic acid (S69D/E) can simulate constitutive phosphorylation. Validation of these mutants should include:

• Sequencing confirmation of the introduced mutations

• Western blotting with phospho-specific and total BIM antibodies following treatment with Erk1/2 activators (e.g., EGF, PMA)

• Assessment of protein stability using cycloheximide chase assays

• Ubiquitination assays to confirm altered proteasomal targeting

• Functional apoptosis assays to determine the impact on cell death regulation

These mutants serve as valuable tools for dissecting the specific consequences of BIM phosphorylation without interference from other regulatory mechanisms or phosphorylation sites .

What high-throughput approaches can be used to study BIM phosphorylation in the context of the apoptosis network?

Apoptosis Phospho Antibody Arrays represent a powerful high-throughput approach for studying BIM phosphorylation in the broader context of apoptosis regulation. These arrays feature:

These arrays allow simultaneous analysis of multiple phosphorylation events across the apoptosis network, including BIM (Ser69/65) in relation to other BCL-2 family members and upstream regulators. This approach is particularly valuable for identifying coordinated phosphorylation patterns in response to specific stimuli or during disease progression .

How can researchers address inconsistent detection of Phospho-BIM (Ser69) in different cell types?

Inconsistent detection of Phospho-BIM (Ser69) across cell types may stem from several factors:

• Variable expression levels of BIM isoforms (particularly BIM EL, which is the primary target for Ser69 phosphorylation)

• Differential activity of Erk1/2 signaling pathways

• Cell type-specific phosphatase activity rapidly removing the phosphorylation

• Proteasomal degradation kinetics varying between cell types

To address these issues, researchers should:

• Optimize cell lysis conditions with multiple phosphatase inhibitors

• Pre-treat cells with proteasome inhibitors (e.g., MG132) to prevent degradation of phosphorylated BIM

• Use positive control cell lines with known high levels of Phospho-BIM (Ser69)

• Consider enriching for phosphorylated proteins using phospho-protein purification kits before western blotting

• Validate findings using alternative detection methods such as mass spectrometry

These approaches can significantly improve detection consistency across different experimental systems .

How should researchers interpret contradictory results between phosphorylation status and functional outcomes in apoptosis assays?

When facing contradictory results between BIM phosphorylation status and apoptotic outcomes, consider the following interpretive framework:

• Temporal dynamics: Phosphorylation may be transient, while functional effects persist longer

• Threshold effects: A certain threshold of phosphorylated BIM may be required before functional consequences manifest

• Compensatory mechanisms: Other BCL-2 family members may compensate for altered BIM function

• Context dependency: The effect of BIM phosphorylation may depend on the specific apoptotic stimulus and cellular context

• Multiple phosphorylation sites: Other phosphorylation sites on BIM may counteract or synergize with Ser69 phosphorylation

To resolve such contradictions, researchers should:

• Perform detailed time-course experiments

• Use multiple complementary approaches to measure apoptosis (e.g., caspase activity, PARP cleavage, annexin V staining)

• Employ genetic approaches (siRNA, CRISPR) to manipulate BIM levels and phosphorylation status

• Consider the broader signaling network context rather than focusing solely on isolated modifications .

What are the most common artifacts in Phospho-BIM (Ser69) detection and how can they be mitigated?

Common artifacts in Phospho-BIM (Ser69) detection include:

• Post-lysis dephosphorylation leading to false negatives

• Non-specific antibody binding causing false positives

• Sample processing-induced stress activating kinase pathways

• Antibody cross-reactivity with similar phospho-epitopes on other proteins

• Cell death-induced proteolysis generating misleading fragments

Mitigation strategies include:

• Immediate processing of samples in ice-cold buffers with freshly added phosphatase inhibitors

• Including both positive controls (growth factor-stimulated cells) and negative controls (Erk inhibitor-treated cells)

• Confirming specificity with phosphatase treatment of duplicate samples

• Validating results with at least two different detection methods

• Using BIM knockout cells as definitive negative controls to identify non-specific bands

These practices significantly improve data reliability and interpretability in phosphorylation studies .

How can researchers distinguish between different phosphorylated species of BIM in complex samples?

Distinguishing between multiple phosphorylated forms of BIM requires sophisticated analytical approaches:

• Two-dimensional gel electrophoresis separating proteins by both molecular weight and isoelectric point, revealing distinct phosphorylated species as separate spots

• Phosphate-affinity SDS-PAGE using Phos-tag™ acrylamide to resolve proteins based on the number and position of phosphorylated residues

• Immunoprecipitation followed by mass spectrometry to identify all phosphorylation sites present

• Sequential immunoblotting with different phospho-specific antibodies

• Lambda phosphatase treatment to confirm phosphorylation-dependent mobility shifts

For quantitative analysis, consider using:

• Parallel reaction monitoring mass spectrometry for absolute quantification of specific phospho-peptides

• Proximity ligation assays to visualize specific phosphorylated forms in situ

• Custom phospho-proteomic arrays targeting multiple BIM phosphorylation sites simultaneously

These approaches enable researchers to dissect the complex patterns of BIM phosphorylation occurring in response to various cellular stimuli and stress conditions .